Andrew D J Pearson, Elly Barry, Yael P Mossé, Franca Ligas, Nick Bird, Teresa de Rojas, Zachary F Zimmerman, Keith Wilner, Willi Woessmann, Susan Weiner, Brenda Weigel, Rajkumar Venkatramani, Dominique Valteau, Toby Trahair, Malcolm Smith, Sonia Singh, Giovanni Selvaggi, Nicole Scobie, Gudrun Schleiermacher, Nicholas Richardson, Julie Park, Karsten Nysom, Koen Norga, Margret Merino, Joe McDonough, Yousif Matloub, Lynley V Marshall, Eric Lowe, Giovanni Lesa, Meredith Irwin, Dominik Karres, Amar Gajjar, François Doz, Elizabeth Fox, Steven G DuBois, Martha Donoghue, Michela Casanova, Hubert Caron, Vickie Buenger, Diana Bradford, Patricia Blanc, Amy Barone, Gregory Reaman, Gilles Vassal
The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums focused on anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. ALK is an important oncogene and target in several paediatric tumours (anaplastic large cell lymphoma [ALCL], inflammatory myofibroblastic tumour [IMT], neuroblastoma and hemispheric gliomas in infants and young children) with unmet therapeutic needs. ALK tyrosine kinase inhibitors have been demonstrated to be active both in ALK fusion-kinase positive ALCL and IMT...
November 2021: European Journal of Cancer